Pasadena Private Wealth’s aTyr Pharma ATYR Stock Holding History

Pasadena Private Wealth’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,228	Closed	-$9.54K	–	327
2026 Q1	$9.54K	Buy	+12,228	New	+$10.3K	﹤0.01%	257

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pasadena Private Wealth's ATYR Position: Q2 2026 in Review

Pasadena Private Wealth sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 12,228 shares — an estimated $9.54K sold.

Pasadena Private Wealth first reported a position in ATYR in Q1 2026 and held it in 1 quarter. The position peaked at $9.54K in Q1 2026. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

Pasadena Private Wealth reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
Pasadena Private Wealth sold 12,228 aTyr Pharma shares in Q2 2026, an estimated $9.54K.
Pasadena Private Wealth first reported a position in aTyr Pharma in Q1 2026 and held it in 1 quarter.
Pasadena Private Wealth's aTyr Pharma position peaked at $9.54K in Q1 2026.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Pasadena Private Wealth's 13F filing for Q2 2026, filed 11 Aug 2026.